Stromal B Lymphocytes Affecting Prognosis in Triple-Negative Breast Cancer by Opal/TSA Multiplexed Immunofluorescence

References

• Sonderstrup IMH, Jensen MB, Ejlertsen B., et al. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA -mutated breast cancer. Acta Oncol. 2019;58(3):363–370. doi:10.1080/0284186X.2018.1539239
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–1281. doi:10.1200/JCO.2007.14.4147
   PubMed Web of Science ®Google Scholar
• Breakthrough of the year 2013. Notable developments. Science. 2013;342(6165):1435–1441. doi:10.1126/science.342.6165.1444
   PubMedGoogle Scholar
• Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1). doi:10.1186/s40425-018-0349-3
   PubMedGoogle Scholar
• Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a Phase 1 Study. JAMA Oncol. 2019;5(1):74–82. doi:10.1001/jamaoncol.2018.4224
   PubMed Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the Phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):397–404. doi:10.1093/annonc/mdy517
   PubMed Web of Science ®Google Scholar
• Schmid D, Park CG, Hartl CA, et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun. 2017;8(1):1747. doi:10.1038/s41467-017-01830-8
   PubMedGoogle Scholar
• Saraiva DP, Guadalupe Cabral M, Jacinto A, Braga S. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open. 2017;2(4):e000208. doi:10.1136/esmoopen-2017-000208
   PubMed Web of Science ®Google Scholar
• Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol. 2013;44(10):2055–2063. doi:10.1016/j.humpath.2013.03.010
   PubMed Web of Science ®Google Scholar
• Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015;33(1):445–474. doi:10.1146/annurev-immunol-032414-112043
   PubMedGoogle Scholar
• Wei B, Yao M, Xing C, et al. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: an updated systematic review and meta-analysis. Onco Targets Ther. 2016;9:5567–5575. doi:10.2147/OTT.S108419
   PubMed Web of Science ®Google Scholar
• Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013;140(1):13–21. doi:10.1007/s10549-013-2618-7
   PubMed Web of Science ®Google Scholar
• Mersin H, Yildirim E, Berberoglu U, Gulben K. The prognostic importance of triple negative breast carcinoma. Breast. 2008;17(4):341–346. doi:10.1016/j.breast.2007.11.031
   PubMed Web of Science ®Google Scholar
• Marginean F, Rakha EA, Ho BC, Ellis IO, Lee AH. Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Mod Pathol. 2010;23(10):1357–1363. doi:10.1038/modpathol.2010.123
   PubMed Web of Science ®Google Scholar
• Kurozumi S, Matsumoto H, Kurosumi M, et al. Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. Oncol Lett. 2019;17(3):2647–2656. doi:10.3892/ol.2019.9938
   PubMed Web of Science ®Google Scholar
• Thommen DS, Koelzer VH, Herzig P, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24(7):994–1004. doi:10.1038/s41591-018-0057-z
   PubMed Web of Science ®Google Scholar
• Kim SK. Genomic Signature of the Standardized Uptake Value in (18)F-Fluorodeoxyglucose Positron Emission Tomography in Breast Cancer. Cancers. 2020;12:1.
   Web of Science ®Google Scholar
• Karn T, Pusztai L, Ruckhäberle E, et al. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer. 2012;48(1):12–23. doi:10.1016/j.ejca.2011.06.025
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Kuroda H, Jamiyan T, Yamaguchi R, et al. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast. BMC Cancer. 2021;21(1):286. doi:10.1186/s12885-021-08009-x
   PubMed Web of Science ®Google Scholar
• Wang J. Multiplexed immunofluorescence identifies high stromal CD68(+)PD-L1(+) macrophages as a predictor of improved survival in triple negative breast cancer. Sci Rep. 2021;11(1):21608. doi:10.1038/s41598-021-01116-6
   PubMed Web of Science ®Google Scholar
• Yeong J, Lim JCT, Lee B, et al. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer. Front Immunol. 2018;9:1209. doi:10.3389/fimmu.2018.01209
   PubMed Web of Science ®Google Scholar
• Ali HR, Provenzano E, Dawson SJ, Blows FM, Caldas CJA. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients25. Ann Oncol. 2014;25(8):1536–1543. doi:10.1093/annonc/mdu191
   PubMed Web of Science ®Google Scholar
• Liu S, Lachapelle J, Leung S, Research DG, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer14. Br Cancer Res. 2012;14(2):R48. doi:10.1186/bcr3148
   PubMed Web of Science ®Google Scholar
• Miyashita M, Sasano H, Tamaki K, et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer. Br Cancer Res. 2015;17(1):124. doi:10.1186/s13058-015-0632-x
   PubMedGoogle Scholar
• Asano Y, Kashiwagi S, Goto W, et al. Tumour‐infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Br J Surg. 2016;103(7):845–854. doi:10.1002/bjs.10127
   PubMed Web of Science ®Google Scholar
• Mella M, Joonas H, Karihtala P. Tumor infiltrating CD8 + T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma. Oncoimmunology. 2015;4(6):e1002726. doi:10.1080/2162402X.2014.1002726
   PubMed Web of Science ®Google Scholar
• Gu-Trantien C, Loi S, Garaud S, Equeter C, Willard-Gallo KJ. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873–2892. doi:10.1172/JCI67428
   PubMed Web of Science ®Google Scholar
• Iglesia MD, Vincent BG, Parker JS, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res. 2014;20(14):3818–3829. doi:10.1158/1078-0432.CCR-13-3368
   PubMed Web of Science ®Google Scholar
• Harris RJ, Cheung A, Ng JCF, et al. Tumor-infiltrating B lymphocyte profiling identifies igg-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer. Cancer Res. 2021;81(16):4290–4304. doi:10.1158/0008-5472.CAN-20-3773
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Lee AHS, Paish EC, et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012;132(2):545–553. doi:10.1007/s10549-011-1620-1
   PubMed Web of Science ®Google Scholar
• Mohammed ZM, Going JJ, Edwards J, et al. The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2012;107(5):864–873. doi:10.1038/bjc.2012.347
   PubMed Web of Science ®Google Scholar
• Schmidt M, Bohm D, von Torne C, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68(13):5405–5413. doi:10.1158/0008-5472.CAN-07-5206
   PubMed Web of Science ®Google Scholar
• Hanker LC, Rody A, Holtrich U, et al. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Res Treat. 2013;137(2):407–416. doi:10.1007/s10549-012-2356-2
   PubMed Web of Science ®Google Scholar
• Schmidt M, Micke P, Gehrmann M, Hengstler JG. Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors. Oncoimmunology. 2012;1(7):1156–1158. doi:10.4161/onci.21653
   PubMed Web of Science ®Google Scholar
• Wennhold K, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. B cell-based cancer immunotherapy. Transfus Med Hemother. 2019;46(1):36–46. doi:10.1159/000496166
   PubMed Web of Science ®Google Scholar
• Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015;36(4):229–239. doi:10.1016/j.it.2015.02.004
   PubMed Web of Science ®Google Scholar
• Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12(1):306. doi:10.1186/1471-2407-12-306
   PubMedGoogle Scholar
• Mehta AK, Kadel S, Townsend MG, Oliwa M, Guerriero JL. Macrophage biology and mechanisms of immune suppression in breast cancer. Front Immunol. 2021;12:643771. doi:10.3389/fimmu.2021.643771
   PubMed Web of Science ®Google Scholar
• Mohammed ZM, Going JJ, Edwards J, McMillan DC. The role of the tumour inflammatory cell infiltrate in predicting recurrence and survival in patients with primary operable breast cancer. Cancer Treat Rev. 2012;38(8):943–955. doi:10.1016/j.ctrv.2012.04.011
   PubMed Web of Science ®Google Scholar
• Murri AM, Hilmy M, Bell J, et al. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer. 2008;99(7):1013–1019. doi:10.1038/sj.bjc.6604667
   PubMed Web of Science ®Google Scholar
• Campbell MJ. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011;128(3):703–711. doi:10.1007/s10549-010-1154-y
   PubMed Web of Science ®Google Scholar
• Beckers RK, Selinger CI, Vilain R, et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 2016;69(1):25–34. doi:10.1111/his.12904
   PubMed Web of Science ®Google Scholar
• Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: current state of the art. Breast. 2017;35:142–150. doi:10.1016/j.breast.2017.07.005
   PubMed Web of Science ®Google Scholar
• Kim IS, Gao Y, Welte T, et al. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat Cell Biol. 2019;21(9):1113–1126. doi:10.1038/s41556-019-0373-7
   PubMed Web of Science ®Google Scholar